Nutrition and Clinical Outcomes in IBD
- Sponsor
- Barts & The London NHS Trust
- Study ID
- NCT06550310
- Status
- Recruiting
Conditions
- Crohn Disease
- Inflammatory Bowel Diseases
- Malnutrition
- Sarcopenia
- Ulcerative Colitis
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The goal of this observational study is to demonstrate that nutritional status and body composition have an impact on clinical outcomes in inflammatory bowel disease (IBD). The main objectives are: 1. To compare the detection rates of undernutrition between a range of nutritional screening tools, physiological measures and assessment tools amongst patients with different IBD phenotypes 2. To correlate nutritional status, nutritional biomarkers and body composition with clinical outcomes in patients with IBD treated with advanced medical therapy or surgery 3. To determine a potential relationship between radiological muscle mass measurements and clinical outcomes in patients with IBD treated with advanced medical therapy or surgery Participants will undergo an assessment at pre-treatment baseline and then again at their scheduled follow-up. This is a non-interventional study and participants will not be required to have any invasive tests or hospital visits beyond that of standard clinical care.
Key Dates
- First listed
- Aug 13, 2024
- Start date
- Oct 24, 2024
- Status verified
- Feb 2026
- Primary completion
- May 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 300 participants (estimated)
Arms
- Arm: Medical treatment groupPatients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) starting a new advanced medical therapy (e.g. biologic or small molecule)
- Arm: Surgical treatment groupPatients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) undergoing an IBD-related surgery
Primary Outcome Measure
Correlation of nutritional parameters (at baseline and during treatment) with pre-defined clinical outcomes in patients undergoing advanced medical therapy (at 14 and 52 weeks). [ Time Frame: 14 and 52 weeks ]
Central Contacts
- Sarah Faloon, MBChB07713444631
- Shameer Mehta, MD020 3594 3500
Find similar trials
Related Studies
- Immune Regulation in Ulcerative Colitis or Crohn s DiseaseRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic TestingRecruiting · University of Chicago · Chicago, Illinois
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Fecal Microbiome TransplantPHASE1 · Enrolling By Invitation · Judith Kelsen · Philadelphia, Pennsylvania